CO2024014595A2 - Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina - Google Patents
Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclinaInfo
- Publication number
- CO2024014595A2 CO2024014595A2 CONC2024/0014595A CO2024014595A CO2024014595A2 CO 2024014595 A2 CO2024014595 A2 CO 2024014595A2 CO 2024014595 A CO2024014595 A CO 2024014595A CO 2024014595 A2 CO2024014595 A2 CO 2024014595A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyrimidin
- cyclin
- substituted
- kinase inhibitors
- dependent kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022090344 | 2022-04-29 | ||
| CN2022105964 | 2022-07-15 | ||
| CN2023085071 | 2023-03-30 | ||
| PCT/CN2023/091483 WO2023208173A1 (en) | 2022-04-29 | 2023-04-28 | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024014595A2 true CO2024014595A2 (es) | 2024-12-30 |
Family
ID=88517887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0014595A CO2024014595A2 (es) | 2022-04-29 | 2024-10-25 | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240300937A1 (enExample) |
| EP (1) | EP4514791A4 (enExample) |
| JP (1) | JP2025516213A (enExample) |
| KR (1) | KR20250004890A (enExample) |
| CN (2) | CN119095840A (enExample) |
| AR (1) | AR129185A1 (enExample) |
| AU (1) | AU2023260284A1 (enExample) |
| CA (1) | CA3256792A1 (enExample) |
| CL (1) | CL2024003269A1 (enExample) |
| CO (1) | CO2024014595A2 (enExample) |
| IL (1) | IL316556A (enExample) |
| MX (1) | MX2024013266A (enExample) |
| TW (1) | TW202400585A (enExample) |
| WO (1) | WO2023208173A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
| EP4791727A1 (en) * | 2023-10-11 | 2026-08-19 | Beone Medicines I GmbH | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| CN118286225A (zh) * | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| WO2022149057A1 (en) * | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
-
2023
- 2023-04-28 IL IL316556A patent/IL316556A/en unknown
- 2023-04-28 JP JP2024563509A patent/JP2025516213A/ja active Pending
- 2023-04-28 KR KR1020247039643A patent/KR20250004890A/ko active Pending
- 2023-04-28 TW TW112115912A patent/TW202400585A/zh unknown
- 2023-04-28 WO PCT/CN2023/091483 patent/WO2023208173A1/en not_active Ceased
- 2023-04-28 CN CN202380036165.1A patent/CN119095840A/zh active Pending
- 2023-04-28 AU AU2023260284A patent/AU2023260284A1/en active Pending
- 2023-04-28 CA CA3256792A patent/CA3256792A1/en active Pending
- 2023-04-28 CN CN202510407101.9A patent/CN120441555A/zh active Pending
- 2023-04-28 EP EP23795605.7A patent/EP4514791A4/en active Pending
- 2023-04-28 AR ARP230101047A patent/AR129185A1/es unknown
-
2024
- 2024-04-01 US US18/623,847 patent/US20240300937A1/en active Pending
- 2024-10-25 CO CONC2024/0014595A patent/CO2024014595A2/es unknown
- 2024-10-25 MX MX2024013266A patent/MX2024013266A/es unknown
- 2024-10-25 CL CL2024003269A patent/CL2024003269A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129185A1 (es) | 2024-07-24 |
| CN120441555A (zh) | 2025-08-08 |
| IL316556A (en) | 2024-12-01 |
| MX2024013266A (es) | 2024-12-06 |
| AU2023260284A1 (en) | 2024-11-14 |
| KR20250004890A (ko) | 2025-01-08 |
| EP4514791A4 (en) | 2026-03-11 |
| EP4514791A1 (en) | 2025-03-05 |
| CL2024003269A1 (es) | 2025-03-07 |
| CN119095840A (zh) | 2024-12-06 |
| US20240300937A1 (en) | 2024-09-12 |
| JP2025516213A (ja) | 2025-05-27 |
| CA3256792A1 (en) | 2023-11-02 |
| TW202400585A (zh) | 2024-01-01 |
| WO2023208173A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007230A2 (es) | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) | |
| ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| CL2024003269A1 (es) | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina | |
| NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| PA8675701A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
| MX2021002998A (es) | Compuestos de triazolo-pirimidina y usos de los mismos. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| PA8680701A1 (es) | Derivados de oxindol | |
| ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CO6612228A2 (es) | Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer | |
| ECSP10010695A (es) | Compuestos de piridina | |
| PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| MX2025001108A (es) | Inhibidores de cinasas aminoheteroarílicos. | |
| UY27452A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer |